Literature DB >> 22542706

Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases.

Susan Guo1, Chandana A Reddy, Samuel T Chao, John H Suh, Gene H Barnett, Michael A Vogelbaum, Gregory M Videtic.   

Abstract

INTRODUCTION: The Graded Prognostic Assessment (GPA) provides prognostic classification for patients with brain metastases (BM), based on Radiation Therapy Oncology Group (RTOG) data. Recent evidence suggests differential response and outcomes to chemotherapy for different non-small cell lung cancer (NSCLC) histologies. Using a large BM patient database, we assessed the impact of histologic subtypes on survival stratified by the GPA.
METHODS: From an IRB-approved database, we analyzed 780 patients with NSCLC BM treated from 1982 to 2004. GPA classification variables included age, KPS, number of BM, and presence of extracranial disease. Histology was identified for each patient. Median survival time (MST) based on GPA class and histology were calculated using Kaplan-Meier analysis. The log rank test was used to determine statistical differences.
RESULTS: MST, in months, by histology were: adenocarcinoma (AC) 6.2 (n=464), large cell (LC) 4.1 (n=98), squamous (SQ) 4.2 (n=108) (p=0.0549). For GPA 3.5-4.0, MSTs did not differ significantly by histology. Differences in MST by histology were noted for GPA 3.0 (p=0.04), GPA 1.5-2.5 (p=0.01), and GPA 0-1.0 (p=0.02). For all patients with brain metastases BM from NSCLC, MSTs by GPA score were: GPA 3.5-4.0, 12.6; GPA 3.0, 10.2; GPA 1.5-2.5, 5.8; and GPA 0-1.0, 2.7.
CONCLUSIONS: Adenocarcinoma showed a statistically significant higher MST than other histologies of NSCLC for patients with GPA 0-3.0. Using histology as a prognostic factor for BM from NSCLC warrants further investigation. Our cohort of NSCLC BM patients validates the GPA, with MST comparable to that of published data.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22542706     DOI: 10.1016/j.lungcan.2012.03.028

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  11 in total

1.  αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer.

Authors:  Anna Sophie Berghoff; Astrid Kerstin Kovanda; Thomas Melchardt; Rupert Bartsch; Johannes A Hainfellner; Bence Sipos; Jens Schittenhelm; Christoph C Zielinski; Georg Widhalm; Karin Dieckmann; Michael Weller; Simon L Goodman; Peter Birner; Matthias Preusser
Journal:  Clin Exp Metastasis       Date:  2014-08-24       Impact factor: 5.150

2.  Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC).

Authors:  Paul Martin Putora; Silvia Ess; Cedric Panje; Thomas Hundsberger; Karin van Leyen; Ludwig Plasswilm; Martin Früh
Journal:  Clin Exp Metastasis       Date:  2015-01-28       Impact factor: 5.150

3.  Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial.

Authors:  Xiao-Xiao Dinglin; Yan Huang; Hui Liu; Yin-Duo Zeng; Xue Hou; Li-Kun Chen
Journal:  J Neurooncol       Date:  2013-02-19       Impact factor: 4.130

4.  Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases.

Authors:  A S Berghoff; A Ilhan-Mutlu; A Wöhrer; M Hackl; G Widhalm; J A Hainfellner; K Dieckmann; T Melchardt; B Dome; H Heinzl; P Birner; M Preusser
Journal:  Strahlenther Onkol       Date:  2014-02-28       Impact factor: 3.621

5.  Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA).

Authors:  Paul W Sperduto; Ryan Shanley; Xianghua Luo; David Andrews; Maria Werner-Wasik; Richard Valicenti; Jean-Paul Bahary; Luis Souhami; Minhee Won; Minesh Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-09-26       Impact factor: 7.038

6.  CAVEOLIN-1 expression in brain metastasis from lung cancer predicts worse outcome and radioresistance, irrespective of tumor histotype.

Authors:  Eleonora Duregon; Rebecca Senetta; Alessandra Pittaro; Ludovica Verdun di Cantogno; Giulia Stella; Pierpaolo De Blasi; Michele Zorzetto; Cristina Mantovani; Mauro Papotti; Paola Cassoni
Journal:  Oncotarget       Date:  2015-10-06

7.  The effect of non-small cell lung cancer histology on survival as measured by the graded prognostic assessment in patients with brain metastases treated by hypofractionated stereotactic radiotherapy.

Authors:  Liang-Hua Ma; Guang Li; Hong-Wei Zhang; Zhi-Yu Wang; Jun Dang; Shuo Zhang; Lei Yao
Journal:  Radiat Oncol       Date:  2016-07-13       Impact factor: 3.481

Review 8.  Brain metastases from hepatocellular carcinoma: recent advances and future avenues.

Authors:  Shanshan Wang; Anqiang Wang; Jianzhen Lin; Yuan Xie; Liangcai Wu; Hanchun Huang; Jin Bian; Xiaobo Yang; Xueshuai Wan; Haitao Zhao; Jiefu Huang
Journal:  Oncotarget       Date:  2017-04-11

9.  Factors Affecting the Survival of Patients with Oligometastatic Non-Small-Cell Lung Cancer: A Meta-Analysis.

Authors:  Yu Shi; Jianxin Yang; Ninghua Yao; Minghai Shao; Wenxiu Ding; Wanrong Jiang; Xinchen Sun
Journal:  Can Respir J       Date:  2019-05-19       Impact factor: 2.409

10.  EMT and acquisition of stem cell-like properties are involved in spontaneous formation of tumorigenic hybrids between lung cancer and bone marrow-derived mesenchymal stem cells.

Authors:  Mei-Hua Xu; Xuan Gao; Dan Luo; Xiang-Dong Zhou; Wei Xiong; Guo-Xiang Liu
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.